Partner Monica Chmielewski was quoted in an article for Wolters Kluwer Health, “Strategic Perspectives: Compliance with Common Rule burden-reduction provisions might be disruptive,” about the implications of recent updates to the Common Rule and their effects on clinical research.
Chmielewski pointed out that the implementation of a policy requiring the use of single Institutional Review Boards (sIRBs) for clinical research involving multiple study sites requires IRBs to determine which one will serve as the reviewing organization. She also noted that IRBs are working together to participate in collaborations in order to agree which will serve as the sIRB and which will cede review. The IRB chosen to serve as the sIRB often requires an agreement with an indemnification commitment and will try to disclaim liability and damages, she said.
(Subscription required.)
Chmielewski pointed out that the implementation of a policy requiring the use of single Institutional Review Boards (sIRBs) for clinical research involving multiple study sites requires IRBs to determine which one will serve as the reviewing organization. She also noted that IRBs are working together to participate in collaborations in order to agree which will serve as the sIRB and which will cede review. The IRB chosen to serve as the sIRB often requires an agreement with an indemnification commitment and will try to disclaim liability and damages, she said.
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”